EMA Authorised: Blenrep (belantamab mafodotin) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EMA authorised Blenrep (belantamab mafodotin) for multiple myeloma, with GSK as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 26/08/2026